
Wegovy HD (7.2 mg) Explained: Who It's For and What It Adds
Wegovy HD is a weekly 7.2 mg semaglutide dose for adults already on 2.4 mg. STEP UP results, side effects vs 2.4 mg, cost, EU/UK status and tirzepatide.
Written by Diana Gangan. Updated November 6, 2026.
Wegovy HD is a once-weekly 7.2 mg dose of semaglutide, approved by the FDA on March 19, 2026, for adults who have tolerated the standard 2.4 mg dose for at least 4 weeks and need more weight loss; in the STEP UP trial it added about 3 percentage points of weight loss over 2.4 mg (20.7% against 17.5% for people who stayed on treatment), with more nausea, vomiting and dysesthesia, a tingling or altered skin sensation. Semaglutide, the medicine in standard Wegovy and Ozempic, mimics a gut hormone called GLP-1 that reduces appetite; Wegovy HD is simply a higher top step, not a starting dose. This guide explains who qualifies, the trial results in people with and without type 2 diabetes, how the side effects compare with 2.4 mg, cost, approval in Europe and the UK, and what can and cannot be said about tirzepatide.
Wegovy HD: The Short Answer
- 1What it is: semaglutide 7.2 mg once a week in a single-dose pen, FDA approved March 19, 2026.
- 2Who it is for: adults already on 2.4 mg for at least 4 weeks, who tolerate it and need more weight loss.
- 3Extra benefit: about 3 points more average weight loss than 2.4 mg at 72 weeks, and roughly twice as many people reached 25% loss.
- 4Trade-off: more nausea and vomiting, and much more dysesthesia (22% against 6% on the label).
- 5Cost: $399 a month self-pay via NovoCare as of November 2026; the savings offer excludes government beneficiaries.
- 6Versus tirzepatide: no head-to-head trial exists, so claims that one beats the other are not settled.
What Is Wegovy HD and When Was It Approved?
The FDA approved Wegovy HD (semaglutide injection 7.2 mg) on March 19, 2026, just 54 days after the application was filed. It was the fourth product approved under the Commissioner's National Priority Voucher pilot. The indication is the same as standard Wegovy for weight: adults with obesity, or adults who are overweight and have at least one weight-related condition, to reduce excess body weight and keep it off, alongside diet and physical activity.
It launched nationwide on April 7, 2026. Like all semaglutide products, Wegovy HD carries a boxed warning about thyroid C-cell tumors seen in rodents, and it must not be used by people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2). For background on how the medicine works, see what Wegovy does.
Who Can Use Wegovy HD?
The label sets a clear gate. In its words, for patients who tolerate the 2.4 mg dosage for at least 4 weeks and for whom additional weight reduction is clinically indicated, the dosage may be increased to a maximum of 7.2 mg once weekly. In plain terms, three things need to be true:
- 1You are already on Wegovy 2.4 mg and have been for at least 4 weeks.
- 2You are tolerating 2.4 mg, meaning side effects are manageable.
- 3You and your prescriber agree that more weight loss is medically worthwhile.
That means you cannot start on 7.2 mg. The label's escalation for standard Wegovy runs 0.25, 0.5, 1, 1.7 and then 2.4 mg, each step lasting 4 weeks, so the earliest point at which 7.2 mg becomes an option is after roughly 20 weeks of treatment. The full schedule is explained in our Wegovy dosing schedule guide, and the related question of skipping the lowest step is covered in can you start Wegovy at 0.5 mg. Many people do well on 2.4 mg and never need the higher dose; 2.4 mg remains the standard Wegovy maintenance dose for most patients.
How Is Wegovy HD Given?
Wegovy HD comes as a 7.2 mg/0.75 mL prefilled single-dose pen. A label update in May 2026 confirmed it is available as a pen only, not as a prefilled syringe. It is injected under the skin once a week on the same day each week, at any time of day, with or without meals, into the abdomen, thigh or upper arm. If you are new to the pens, our guide on how to use the Wegovy pen walks through the basics.
What Were the Wegovy 7.2 mg Results in STEP UP?
STEP UP was a 72-week, Novo Nordisk-funded trial in 1,407 adults with a body mass index (BMI) of 30 or more and no diabetes. People were randomly assigned to 7.2 mg, 2.4 mg or placebo. Results are reported two ways. The efficacy estimand (the on-treatment result) estimates what happens if people take the drug as intended; the treatment-policy estimand counts everyone randomized, including people who stopped, so it gives smaller numbers closer to everyday practice.
On the efficacy estimand, average weight loss was 20.7% on 7.2 mg, 17.5% on 2.4 mg and 2.4% on placebo. On the treatment-policy estimand, it was 18.7%, 15.6% and 3.9%. The bigger difference was at the top end: about a third of people on 7.2 mg lost a quarter or more of their body weight, roughly double the share on 2.4 mg.
Wegovy 7.2 mg results: STEP UP and STEP UP T2D (72 weeks)
STEP UP: mean weight loss, efficacy estimand
20.7%
17.5%
2.4%
STEP UP: mean weight loss, treatment-policy
18.7%
15.6%
3.9%
STEP UP: lost 20% or more (treatment-policy)
47.7%
33.3%
Not reported
STEP UP: lost 25% or more (treatment-policy)
31.2%
15.3%
Not reported
STEP UP: lost 25% or more (efficacy estimand)
33.2%
16.7%
0.0%
STEP UP T2D: mean weight loss, efficacy estimand
14.1%
Not reported here
Not reported here
STEP UP T2D: mean weight loss, treatment-policy
13.2%
10.4%
About 3.9%
STEP UP T2D: lost 10% or more
62.9%
51.5%
Not reported here
STEP UP T2D: lost 15% or more
41.2%
28.9%
Not reported here
STEP UP T2D: lost 20% or more
21.3%
14.4%
Not reported here
These are averages; individual results vary widely. For the bigger picture on expected results across doses, see how much weight can you lose on Wegovy.
How Did Wegovy 7.2 mg Do in People With Type 2 Diabetes?
STEP UP T2D enrolled 512 adults with obesity and type 2 diabetes for 72 weeks. On 7.2 mg, average weight loss was 14.1% on the efficacy estimand. On the treatment-policy estimand, it was 13.2% on 7.2 mg against 10.4% on 2.4 mg, with placebo around 3.9% according to the trial's press release. About 21% of people on 7.2 mg lost 20% or more of their body weight, against about 14% on 2.4 mg.
WebMD reported that blood sugar lowering at 7.2 mg was similar to lower doses, so the higher dose adds weight loss rather than extra glucose control.
Are Wegovy 7.2 mg Side Effects Worse Than 2.4 mg?
Somewhat, yes. The label pools two 72-week trials and lists the reactions that were more common on 7.2 mg than on 2.4 mg. Most digestive effects rose a little; dysesthesia rose a lot. Figures are from 303 people on placebo, 304 on 2.4 mg and 1,311 on 7.2 mg.
Wegovy HD side effects: 7.2 mg vs 2.4 mg vs placebo (US label, 72 weeks)
Nausea
13%
35%
39%
Vomiting
6%
16%
22%
Dysesthesia (altered skin sensation)
0%
6%
22%
Constipation
8%
19%
20%
Abdominal pain
7%
9%
12%
Fatigue
5%
9%
11%
Hair loss
1%
3%
6%
Dizziness
1%
5%
6%
Despite this, stopping because of side effects was no more common: 5% stopped on 7.2 mg and 5% on 2.4 mg, against 2% on placebo, and gastrointestinal side effects caused 3% to stop in both active groups. In the published STEP UP paper, serious adverse events were reported in 6.8% on 7.2 mg, 10.9% on 2.4 mg and 5.5% on placebo. Hair loss rose from 3% to 6%; see whether Wegovy causes hair loss.
What Is Dysesthesia, and How Common Is It on Wegovy HD?
Dysesthesia means an unusual or unpleasant skin sensation, such as tingling, prickling, burning, numbness or skin that feels sensitive to touch. On the label it is a grouped term that includes paresthesia (pins and needles) and related terms. It affected 22% of people on 7.2 mg, 6% on 2.4 mg and 0% on placebo in the label data; the STEP UP publication reported 22.9%, 6.0% and 0.5%.
According to WebMD's report on the approval, these skin sensation changes usually improved on their own or after the dose was lowered, and only a small number of people stopped treatment because of them. If you notice tingling or burning skin after moving to 7.2 mg, tell your prescriber rather than stopping on your own; stepping back to 2.4 mg is one option they may consider.
How Much Does Wegovy HD Cost, and Does Insurance Cover It?
As of November 2026, NovoCare lists Wegovy HD at $399 a month for self-pay patients. For people with commercial insurance that covers Wegovy, Novo Nordisk's savings offer can bring the cost down to as little as $25, with a maximum saving of $100 a month. Government beneficiaries, such as people with Medicare or Medicaid, are excluded from that savings offer. A separate $199 introductory price that NovoCare lists through December 31, 2026, applies to the 0.25 mg and 0.5 mg starting doses, not to Wegovy HD.
Whether a given insurance plan covers the 7.2 mg dose specifically was not something we could verify, so check directly with your plan before switching. For a broader look at Wegovy prices and savings programs, see our Wegovy cost and savings card guide.
Is Wegovy 7.2 mg Approved in the EU and UK?
Yes, in both, with some differences from the US. In the European Union, the European Commission approved the 7.2 mg dose in February 2026, after a positive opinion from the EMA's medicines committee in December 2025. At first, the dose was given as three 2.4 mg injections in one sitting. Novo Nordisk announced on July 15, 2026, that a single-dose 7.2 mg pen had also been approved in the EU.
In the UK, the MHRA authorised the 7.2 mg dose in January 2026, again initially as three 2.4 mg injections on the same day. A single-dose 7.2 mg pen was approved on April 14, 2026. The UK authorisation for the higher dose is narrower than in the US: it is for adults with a BMI of 30 or more only, not for people with a BMI below 30 and not for the cardiovascular risk indication.
How Does Wegovy HD Compare With Tirzepatide 15 mg?
There is no head-to-head trial of semaglutide 7.2 mg against tirzepatide 15 mg (Zepbound), so any direct ranking is uncertain. Comparing separate trials is risky because populations and methods differ. With that caveat, in SURMOUNT-1, a 72-week trial in adults without diabetes, tirzepatide 15 mg produced 20.9% average weight loss against 3.1% on placebo, and 57% of people on 15 mg lost 20% or more.
An indirect comparison funded by Eli Lilly, which makes tirzepatide, was presented at the EASD meeting in 2026. It estimated that tirzepatide 15 mg led to 4.5 percentage points more weight loss than semaglutide 7.2 mg on the treatment-regimen estimand, a statistically significant difference, but only 1.8 points on the efficacy estimand, which was not significant. The analysis was described as hypothesis-generating, meaning it raises a question for a proper trial rather than answering it. For how the standard doses compare, see Zepbound vs Wegovy.
When to Talk to Your Doctor
- 1You have been on 2.4 mg for at least 4 weeks, are tolerating it, and your weight loss has stalled.
- 2You have tingling, burning, numbness or unusual skin sensitivity after moving to 7.2 mg.
- 3You have severe or persistent nausea or vomiting, or cannot keep fluids down.
- 4You have severe stomach pain that spreads to your back, which can be a sign of pancreatitis.
- 5You notice a lump or swelling in your neck, trouble swallowing or a persistent hoarse voice.
- 6You have type 2 diabetes and take insulin or a sulfonylurea, as the risk of low blood sugar needs monitoring.
Questions to Ask Your Doctor About Wegovy HD
These questions can help you decide together whether the higher dose is worth it:
- 1Is my weight loss on 2.4 mg enough for my health goals, or is more clinically indicated?
- 2Are my current side effects mild enough to try 7.2 mg?
- 3What should I do if I get dysesthesia or worse nausea after switching?
- 4Could I move back to 2.4 mg if 7.2 mg does not suit me?
- 5Does my insurance cover the 7.2 mg pen, and what will I pay each month?
- 6Are there other reasons my weight loss has slowed that we should look at first?
A plateau does not always mean a higher dose is needed, as discussed in why am I not losing weight on Wegovy.
The 7.2 mg dose has its own stomach side-effect data in the label, including constipation. For causes and what helps, see Wegovy constipation.
The Bottom Line
Wegovy HD gives people who have already reached and tolerated 2.4 mg a further step up. In STEP UP, 7.2 mg added about 3 percentage points of average weight loss over 2.4 mg and roughly doubled the share of people losing a quarter of their body weight, while people with type 2 diabetes saw a smaller but still meaningful gain. The cost is more nausea and vomiting and a notable rise in skin sensation changes, which usually settle. It is not a starting dose, and whether it beats tirzepatide is unknown.
FAQ
Yes. The US label allows 7.2 mg only for people who have tolerated 2.4 mg for at least 4 weeks and need more weight loss.
In STEP UP, people without diabetes lost 20.7% on average if they stayed on treatment, or 18.7% counting everyone randomized, after 72 weeks. People with type 2 diabetes lost less, about 13% to 14%.
Nobody knows yet. There is no head-to-head trial; a Lilly-funded indirect comparison favoured tirzepatide 15 mg but was described as hypothesis-generating.
The cause is not known. Dysesthesia affected 22% of people on 7.2 mg in label data and usually improved on its own or with a lower dose.
NovoCare lists Wegovy HD at $399 a month for self-pay patients as of November 2026.
No. You first step up through 0.25, 0.5, 1, 1.7 and 2.4 mg, then need at least 4 weeks on 2.4 mg before 7.2 mg is an option.
Sources
- 1U.S. Food and Drug Administration. FDA approves fourth product under National Priority Voucher program: higher-dose semaglutide, FDA, 2026
- 2Novo Nordisk. WEGOVY (semaglutide) injection prescribing information, revised 03/2026, FDA, 2026
- 3Novo Nordisk. WEGOVY (semaglutide) prescribing information, revised 05/2026, FDA, 2026
- 4The Medical Letter. Semaglutide 7.2 mg (Wegovy HD) for weight management, Medical Letter on Drugs and Therapeutics, 2026
- 5Wharton S et al. STEP UP trial of semaglutide 7.2 mg, as summarized in What pharmacists should know about high-dose semaglutide's safety profile, Lancet Diabetes & Endocrinology 2025 / Pharmacy Times
- 6Novo Nordisk. STEP UP trial headline results for semaglutide 7.2 mg, Novo Nordisk, 2025
- 7Novo Nordisk. Wegovy HD (semaglutide 7.2 mg) approved in the US, BioSpace, 2026
- 8Novo Nordisk. Wegovy HD available now nationwide, BioSpace, 2026
- 9STEP UP T2D results press release, EurekAlert!, 2025
- 10NovoCare. Wegovy pricing and savings, Novo Nordisk, accessed November 6, 2026
- 11Novo Nordisk. European Commission approves 7.2 mg dose of injectable Wegovy, BioSpace, 2026
- 12Novo Nordisk. European Commission approval of single ready-to-use pen for 7.2 mg, BioSpace, 2026
- 13MHRA. Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity, GOV.UK, 2026
- 14Weekly tirzepatide confers substantial weight loss in obesity without diabetes (SURMOUNT-1), Healio, 2022
- 15Tirzepatide linked to more weight loss than semaglutide 7.2 mg, Pharmacy Times, 2026
- 16FDA approves Wegovy HD, WebMD, 2026
This article is general information, not medical advice. The STEP UP trials were funded by Novo Nordisk, which makes Wegovy; the indirect comparison with tirzepatide was funded by Eli Lilly, which makes Zepbound.

Diana Gangan
Author
Comments (0)
Be the first to comment on this article.




